Cargando…

Nanomedicine for the reduction of the thrombogenicity of stent coatings

The treatment of patients with drug-eluting stents (DES) continues to evolve with the current emergence of DES technology that offers a combination of pharmacological and mechanical approaches to prevent arterial restenosis. However, despite the promising short-term and mid-term outcomes of DES, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Karagkiozaki, Varvara C, Logothetidis, Stergios D, Kassavetis, Spyridon N, Giannoglou, George D
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865019/
https://www.ncbi.nlm.nih.gov/pubmed/20463940
_version_ 1782180824669487104
author Karagkiozaki, Varvara C
Logothetidis, Stergios D
Kassavetis, Spyridon N
Giannoglou, George D
author_facet Karagkiozaki, Varvara C
Logothetidis, Stergios D
Kassavetis, Spyridon N
Giannoglou, George D
author_sort Karagkiozaki, Varvara C
collection PubMed
description The treatment of patients with drug-eluting stents (DES) continues to evolve with the current emergence of DES technology that offers a combination of pharmacological and mechanical approaches to prevent arterial restenosis. However, despite the promising short-term and mid-term outcomes of DES, there are valid concerns about adverse clinical effects of late stent thrombosis. In this study, we present an example of how nanomedicine can offer solutions for improving stent coating manufacturing, by producing nanomaterials with tailored and controllable properties. The study is based on the exploitation of human platelets response towards carbon-based nanocoatings via atomic force microscope (AFM). AFM can facilitate the comprehensive analysis of platelets behavior onto stent nanocoatings and enable the study of thrombogenicity. Platelet-rich plasma from healthy donors was used for the real-time study of biointerfacial interactions. The carbon nanomaterials were developed by rf magnetron sputtering technique under controllable deposition conditions to provide favorable surface nanotopography. It was shown that by altering the surface topography of nanocoatings, the activation of platelets can be affected, while the carbon nanocoatings having higher surface roughness were found to be less thrombogenic in terms of platelets adhesion. This is an actual solution for improving the stent coating fabrication.
format Text
id pubmed-2865019
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28650192010-05-12 Nanomedicine for the reduction of the thrombogenicity of stent coatings Karagkiozaki, Varvara C Logothetidis, Stergios D Kassavetis, Spyridon N Giannoglou, George D Int J Nanomedicine Original Research The treatment of patients with drug-eluting stents (DES) continues to evolve with the current emergence of DES technology that offers a combination of pharmacological and mechanical approaches to prevent arterial restenosis. However, despite the promising short-term and mid-term outcomes of DES, there are valid concerns about adverse clinical effects of late stent thrombosis. In this study, we present an example of how nanomedicine can offer solutions for improving stent coating manufacturing, by producing nanomaterials with tailored and controllable properties. The study is based on the exploitation of human platelets response towards carbon-based nanocoatings via atomic force microscope (AFM). AFM can facilitate the comprehensive analysis of platelets behavior onto stent nanocoatings and enable the study of thrombogenicity. Platelet-rich plasma from healthy donors was used for the real-time study of biointerfacial interactions. The carbon nanomaterials were developed by rf magnetron sputtering technique under controllable deposition conditions to provide favorable surface nanotopography. It was shown that by altering the surface topography of nanocoatings, the activation of platelets can be affected, while the carbon nanocoatings having higher surface roughness were found to be less thrombogenic in terms of platelets adhesion. This is an actual solution for improving the stent coating fabrication. Dove Medical Press 2010 2010-04-07 /pmc/articles/PMC2865019/ /pubmed/20463940 Text en © 2010 Karagkiozaki et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Karagkiozaki, Varvara C
Logothetidis, Stergios D
Kassavetis, Spyridon N
Giannoglou, George D
Nanomedicine for the reduction of the thrombogenicity of stent coatings
title Nanomedicine for the reduction of the thrombogenicity of stent coatings
title_full Nanomedicine for the reduction of the thrombogenicity of stent coatings
title_fullStr Nanomedicine for the reduction of the thrombogenicity of stent coatings
title_full_unstemmed Nanomedicine for the reduction of the thrombogenicity of stent coatings
title_short Nanomedicine for the reduction of the thrombogenicity of stent coatings
title_sort nanomedicine for the reduction of the thrombogenicity of stent coatings
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865019/
https://www.ncbi.nlm.nih.gov/pubmed/20463940
work_keys_str_mv AT karagkiozakivarvarac nanomedicineforthereductionofthethrombogenicityofstentcoatings
AT logothetidisstergiosd nanomedicineforthereductionofthethrombogenicityofstentcoatings
AT kassavetisspyridonn nanomedicineforthereductionofthethrombogenicityofstentcoatings
AT giannoglougeorged nanomedicineforthereductionofthethrombogenicityofstentcoatings